- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02721186
Effectiveness of Mass Drug Administration for Reducing Seasonal Malaria Transmission in Zanzibar (MaDrAZ)
Effectiveness of Mass Drug Administration (MDA) for Reducing Seasonal Malaria Transmission Towards Its Elimination in Hotspot Areas in Zanzibar - a Cluster-randomised Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study design: This is a cluster-randomised controlled study with two arms: an intervention arm with two rounds of MDA with dihydroartemisinin-piperaquine (DHAp) + single low dose (SLD) primaquine, and a control arm with no MDA.
Study site and study population: The study will be conducted in 16 hotspot Shehias (8 Shehias randomly allocated to each arm), in three districts (West, Central and South districts) in Unguja Island, Zanzibar. Hotspot Shehias [Shehia being the smallest administrative structure in Zanzibar] are defined as Shehias with an annual malaria incidence of >0.8%, calculated as the number of confirmed malaria infections notified at health facilities and during active case detection in 2015 / Shehia projected population for 2015. The study population will include all consenting residents of the selected Shehias, reaching approximately 24000 people.
Study implementation: Two rounds of MDA with DHAp (D-ARTEPP, Guilin Pharmaceutical (Shanghai) Co., Ltd., China) and SLD (0.25mg/kg) primaquine (Primaquine, Remedica Ltd.,Cyprus ) will be conducted approximately four weeks apart in the intervention Shehias, at the anticipated lowest point of malaria transmission prior to the onset of malaria transmission associated with the main rains in April-June 2016. The first drug dose including DHAp and SLD primaquine will be given under supervision whenever possible; the other two doses of the standard once daily DHAp regimen will be taken unsupervised at home. Labelled packets containing all three doses will be left with the head of household with clear instructions for individuals not present at the time of the household visit.
Study objectives: The primary objective of the study is to determine the effectiveness of two rounds of MDA with DHAp + SLD primaquine for reducing seasonal malaria transmission in Shehias considered hotspots on Unguja Island, Zanzibar. The secondary objectives of the study include determining MDA coverage, compliance, and safety after one and two rounds of DHAp + SLD primaquine.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Urban District, Zanzibar
-
Mwanakwerekwe, Urban District, Zanzibar, Tanzania
- Zanzibar Malaria Elimination Programme
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Permanent or temporary resident of study Shehias (i.e., persons who stayed in the selected household the night before the interview)
- Provision of informed consent (refusal must be recorded)
- Age >6 months
Exclusion Criteria:
- Women pregnant in first trimester (assessed by a specific set of questions designed to exclude pregnancy)
- Severe disease that requires immediate referral to health facility or hospital
- Concurrent antimalarial treatment at time of MDA or during the last 14 days
- Inability to take oral medication
Additional exclusion criteria for treatment with SLD Primaquine:
- Pregnancy (all trimesters, assessed by a specific set of questions designed to exclude pregnancy)
- Women breast feeding infants aged < 6months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MDA with DHAp and SLD Primaquine
MDA will be conducted at two time points with an approximate four-week interval.
All consenting and eligible community members will be administered age-appropriate treatment dose of dihydroartemisinin-piperaquine (D-ARTEPP, Guilin Pharmaceutical (Shanghai) Co., Ltd., China) and single low dose (0.25mg/kg) primaquine (Primaquine, Remedica Ltd., Cyprus) in house-to-house campaigns.
|
Other Names:
|
No Intervention: Control
The control arm (no MDA) will have the standard care offered by the Ministry of Health and Social welfare which applies to both arms.
This includes passive case detection of individuals seeking treatment at local health facilities, and universal coverage of long lasting insecticide treated bed nets and indoor residual spraying in the study areas.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative notified malaria incidence in the MDA and control Shehias
Time Frame: 6 months after second round of MDA
|
Cumulative notified malaria incidence determined as the number of confirmed malaria cases notified at health facilities (monitored through the malaria case notification system during the period of six months) over the Shehia population size determined by population enumeration at the time of the intervention.
|
6 months after second round of MDA
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PCR determined community prevalence of Plasmodium infections in the MDA and control Shehias
Time Frame: Baseline and 3 months after second round of MDA
|
PCR determined community prevalence of Plasmodium infections determined by cross-sectional screening in every other household in the study area at the time of the first round of MDA, and at six months after the second round of MDA.
|
Baseline and 3 months after second round of MDA
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Population coverage of the MDA intervention at each round
Time Frame: Through completion of first and second round of MDA, i.e. 15 days and 48 days after initiation of MDA, respectively.
|
MDA coverage determined as the number of administered DHAp and SLD primaquine doses during the first and second round of MDA, over over the Shehia population size determined by population enumeration at the time of the intervention.
|
Through completion of first and second round of MDA, i.e. 15 days and 48 days after initiation of MDA, respectively.
|
Proportion of population receiving two rounds of MDA
Time Frame: Through completion of the second round of MDA, i.e. 48 days after initiation of MDA.
|
The proportion of the population having received zero, one or two rounds of MDA.
Refusal and reason for refusal to participate will be recorded.
|
Through completion of the second round of MDA, i.e. 48 days after initiation of MDA.
|
Population compliance to the MDA intervention at each round
Time Frame: 7 days after both first and second round of MDA
|
MDA compliance, i.e. the proportion of the population that have taken one, two or all three doses of DHAp + SLD primaquine, will be evaluated in a subset of the population by post-MDA surveys conducted seven days after the initiation of each MDA round.
The post MDA surveys will include both a questionnaire and finger prick blood sampling for measuring piperaquine blood concentrations.
|
7 days after both first and second round of MDA
|
Occurence of adverse events after MDA with DHAp and SLD primaquine
Time Frame: 14 days after both first and second round of MDA
|
A brief questionnaire will be conducted in a subset of the population during post-MDA surveys conducted seven days after the initiation of each MDA round.
The questionnaire will include specific questions regarding adverse events such as vomiting, nausea, gastrointestinal upset, rash and fatigue.
Severe adverse events, especially symptoms of haemolysis, will be captured at health facilities where haemoglobin and dark urine (representing haemolysis) will be measured and reported using the pharmacovigilance forms and the Primaquine Roll Out Monitoring Pharmacovigilance Tool (PROMPT) developed by the Global Health Group at University of California San Francisco.
|
14 days after both first and second round of MDA
|
Cumulative notified malaria incidence in the MDA and control Shehias during the following high transmission season.
Time Frame: 15 months after second round of MDA
|
Cumulative notified malaria incidence during the following high transmission season, monitored through the malaria case notification system, to assess the long-term effectivness of MDA.
|
15 months after second round of MDA
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Anders Björkman, MD, PhD, Karolinska Institutet
- Principal Investigator: Abdullah S Ali, Programme Manager, Zanzibar Malaria Elimination Programme
Publications and helpful links
General Publications
- Shah MP, Hwang J, Choi L, Lindblade KA, Kachur SP, Desai M. Mass drug administration for malaria. Cochrane Database Syst Rev. 2021 Sep 29;9(9):CD008846. doi: 10.1002/14651858.CD008846.pub3.
- Morris U, Msellem MI, Mkali H, Islam A, Aydin-Schmidt B, Jovel I, Shija SJ, Khamis M, Ali SM, Hodzic L, Magnusson E, Poirot E, Bennett A, Sachs MC, Tarning J, Martensson A, Ali AS, Bjorkman A. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting-high coverage and safety, but no significant impact on transmission. BMC Med. 2018 Dec 10;16(1):215. doi: 10.1186/s12916-018-1202-8.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MaDrAZ-001
- ZAMREC/0001/January/2016 (Other Identifier: Zanzibar Medical Research Ethical Committee)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Syamsudin Abdillah,Ph.D, Pharm DCipto Mangunkusumo Hospital; PT Natura Nuswantara NirmalaCompletedInfections | Malaria | Malaria, Vivax | Uncomplicated Malaria | Malaria,Falciparum | Uncomplicated Plasmodium FalciparumIndonesia
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
Clinical Trials on MDA with DHAp and SLD Primaquine
-
PATHTulane University; Ministry of Health, Zambia; Minister of Community Development...CompletedMalaria | Malaria, FalciparumZambia
-
London School of Hygiene and Tropical MedicineMedical Research Council Unit, The GambiaTerminated
-
London School of Hygiene and Tropical MedicineRadboud University Medical Center; Centre national de recherche et de formation...CompletedMalaria | Plasmodium Falciparum | Asymptomatic MalariaBurkina Faso
-
Indonesia UniversityCompleted
-
Professor Anders BjörkmanUppsala University; Ministry of Health and Social Welfare, Zanzibar; Zanzibar...CompletedPlasmodium Falciparum MalariaTanzania
-
Dr. Prayuth SudathipMedicines for Malaria VentureCompletedMalaria, Vivax | G6PD DeficiencyThailand
-
Armauer Hansen Research Institute, EthiopiaUnited States Agency for International Development (USAID); Tulane University; Addis Continental Institute of Public Health and other collaboratorsUnknown
-
London School of Hygiene and Tropical MedicineCompleted
-
Assaf-Harofeh Medical CenterUnknown
-
Institute of Hematology & Blood Diseases HospitalRecruiting